Search research articles
Contact Us
Filters
Showing results (281-290 of 299) with videos related to
Page
of 30
Sort By:
The Lancet. Oncology
|
September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
Kevin B Kim, Richard Kefford, Anna C Pavlick, et al.
The Lancet. Oncology
|
August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Tony Reid, Bryan Oronsky, Jan Scicinski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J F Liu, K N Moore, M J Birrer, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy
Daniel N Cohen, Steven K Lawson, Aaron C Shaver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
A Italiano, J R Infante, G I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.
The Lancet. Oncology
|
July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Page
of 30
Search research articles
Search
Showing results (281-290 of 299) with videos related to
Sort By:
Page
of 30
The Lancet. Oncology
|
September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
Kevin B Kim, Richard Kefford, Anna C Pavlick, et al.
The Lancet. Oncology
|
August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Tony Reid, Bryan Oronsky, Jan Scicinski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J F Liu, K N Moore, M J Birrer, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy
Daniel N Cohen, Steven K Lawson, Aaron C Shaver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
A Italiano, J R Infante, G I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.
The Lancet. Oncology
|
July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Page
of 30